Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection

References

• World Health OrganizationGuidelines for the Screening, Care and Treatment of Persons with Hepatitis C InfectionGenevaWorld Health Organization2014
   Google Scholar
• SmithBDMorganRLBeckettGACenters for Disease Control and PreventionRecommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965MMWR Recomm Rep201261RR–413222895429
   PubMedGoogle Scholar
• Hepatitis C Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C [webpage on the Internet]. American Association for the Study of Liver Diseases (AASLD), Infectious Diseases Society of America (IDSA) Available from: http://www.hcvguidelines.org/Accessed September 10, 2015
   Google Scholar
• Viekira Pak (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) copackaged for oral use [prescribing information]North ChicagoAbbVie Inc2015
   Google Scholar
• Pilot-MatiasTTripathiRCohenDIn vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450Antimicrob Agents Chemother201559298899725451053
   PubMed Web of Science ®Google Scholar
• GentileIBorgiaFBuonomoARZappuloECastaldoGBorgiaGABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infectionCurr Med Chem201421283261327025005190
   PubMed Web of Science ®Google Scholar
• BadriPDuttaSCoakleyEPharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvirAm J Transplant20151551313132225708713
   PubMed Web of Science ®Google Scholar
• FridellRAQiuDValeraLWangCRoseREGaoMDistinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052J Virol201185147312732021593143
   PubMed Web of Science ®Google Scholar
• DeGoeyDARandolphJTLiuDDiscovery of ABT-267, a pan-genotypic inhibitor of HCV NS5AJ Med Chem20145752047205724400777
   PubMed Web of Science ®Google Scholar
• LeeCDaclatasvir: potential role in hepatitis CDrug Des Devel Ther2013712231233
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARBorgiaGOmbitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infectionExpert Rev Anti Infect Ther20141291033104325074011
   PubMed Web of Science ®Google Scholar
• KrishnanPBeyerJMistryNIn vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5AAntimicrob Agents Chemother201559297998725451055
   PubMed Web of Science ®Google Scholar
• KatiWKoevGIrvinMIn vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitorAntimicrob Agents Chemother20155931505151125534735
   PubMed Web of Science ®Google Scholar
• GentileIBuonomoARBorgiaGDasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infectionRev Recent Clin Trials20149211512324882169
   PubMedGoogle Scholar
• KhatriAMenonRMarburyTCPharmacokinetics and safety of coadministered paritaprevir plus ritonavir (paritaprevir/r), ombitasvir, and dasabuvir in hepatic impairmentJ Hepatol Epub2015610
   Google Scholar
• FeldJJKowdleyKVCoakleyETreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171594160324720703
   PubMed Web of Science ®Google Scholar
• ZeuzemSJacobsonIMBaykalTRetreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirinN Engl J Med2014370171604161424720679
   PubMed Web of Science ®Google Scholar
• FerenciPBernsteinDLalezariJPEARL-III Study; PEARL-IV StudyABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCVN Engl J Med2014370211983199224795200
   PubMed Web of Science ®Google Scholar
• AndreonePColomboMGEnejosaJVABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infectionGastroenterology20141472359365.e124818763
   PubMed Web of Science ®Google Scholar
• KumadaHChayamaKRodriguesLJrRandomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosisHepatology Epub201573
   Google Scholar
• PoordadFHezodeCTrinhRABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisN Engl J Med2014370211973198224725237
   PubMed Web of Science ®Google Scholar
• FeldJJMorenoCTrinhRTurquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis[Abstract P226.] 15th Annual International Symposium on Viral Hepatitis and Liver DiseaseJune 26–28 2015Berlin, Germany
   Google Scholar
• ChayamaKNotsumataKKurosakiMRandomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patientsHepatology20156151523153225644279
   PubMed Web of Science ®Google Scholar
• SulkowskiMSEronJJWylesDOmbitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trialJAMA2015313121223123125706092
   PubMed Web of Science ®Google Scholar
• KwoPYMantryPSCoakleyEAn interferon-free antiviral regimen for HCV after liver transplantationN Engl J Med2014371252375238225386767
   PubMed Web of Science ®Google Scholar
• Toussaint-MillerKAAndresJTreatment considerations for unique patient populations with HCV genotype 1 infectionAnn Pharmacother20154991015103026139639
   PubMed Web of Science ®Google Scholar
• GrahamCSBadenLRYuEInfluence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysisClin Infect Dis200133456256911462196
   PubMed Web of Science ®Google Scholar
• PockrosPJReddyKRMantryPSL01 : safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV GT1 infection in patients with severe renal impairment or end-stage renal disease: the Ruby-I studyJ Hepatol201562S257S261
   PubMed Web of Science ®Google Scholar
• MenonRMBadriPSWangTDrug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvirJ Hepatol2015631202925646891
   PubMed Web of Science ®Google Scholar
• LalezariJSullivanJGVarunokPOmbitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphineJ Hepatol201563236436925839406
   PubMed Web of Science ®Google Scholar
• BurgessSPartoviNYoshidaEMErbSRAzalgaraVMHussainiTDrug interactions with direct-acting antivirals for hepatitis C: implications for HIV and transplant patientsAnn Pharmacother201549667468725770114
   PubMed Web of Science ®Google Scholar
• SorianoVLabargaPBarreiroPDrug interactions with new hepatitis C oral drugsExpert Opin Drug Metab Toxicol201511333334125553890
   PubMed Web of Science ®Google Scholar
• SimmondsPGenetic diversity and evolution of hepatitis C virus – 15 years onJ Gen Virol200485Pt 113173318815483230
   PubMed Web of Science ®Google Scholar
• RongLDahariHRibeiroRMPerelsonASRapid emergence of protease inhibitor resistance in hepatitis C virusSci Transl Med201023030ra32
   PubMed Web of Science ®Google Scholar
• HalfonPLocarniniSHepatitis C virus resistance to protease inhibitorsJ Hepatol201155119220621284949
   PubMed Web of Science ®Google Scholar
• KuntzenTTimmJBericalANaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology20084861769177819026009
   PubMed Web of Science ®Google Scholar
• WylesDLGutierrezJAImportance of HCV genotype 1 subtypes for drug resistance and response to therapyJ Viral Hepat201421422924024597691
   PubMed Web of Science ®Google Scholar
• LontokEHarringtonPHoweAHepatitis C virus drug resistance-associated substitutions: state of the art summaryHepatology Epub2015610
   Google Scholar